| Name | Title | Contact Details |
|---|
As a leading DSO, Heartland Dental provides supported dentists, hygienists, and non-clinical team members with world-class non-clinical administrative support to help them achieve sustainable professional and personal growth. What started from the entrepreneurial spirit of Rick Workman, DMD, with a single dental practice, has evolved into supporting over 2,700 dentists in over 1,700 dental offices across 38 states. Heartland Dental is not your typical Dental Support Organization. Its legacy of being built by a dentist, for dentists along with its doctor-led culture and business model enables supported doctors to be the leaders of their practice, working with their teams to focus on providing great dentistry while Heartland Dental focuses on providing support for the day-to-day non-clinical administrative workflow. You can discover more about Heartland Dental`s Doctor Difference by visiting www.heartland.com. Mission: To support doctors and their teams as they deliver the highest quality dental care and experiences to the communities they serve while providing exceptional careers and creating value for our stakeholders.
Vericred, Inc. is a healthcare data services company, operating at the intersection of health insurance and technology. Vericred serves companies who are transforming today`s healthcare experience, from care management to finding the right insurance plan. Its datasets are the foundation on which the healthcare industry builds innovative solutions. Vericred`s health insurance data platform, which is comprised of plan design and rate data, provider-network data and formulary data, offers a solution to an industry plagued by highly fragmented, rapidly changing data that currently exists in non-standard and non-structured formats.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Driven by a vision to liberate patients from degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicines. Founded in 2016, BlueRock and its team of preeminent scientists are pioneering cell therapies that restore critical natural functions in the body, with an initial focus on severe brain and heart conditions. BlueRock`s culture is defined by scientific transparency, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit.
Belmont Manor Nursing Home Inc is a Belmont, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.